Preferred Label : Anti-PD-1/Anti-PD-L1 Bispecific Antibody CTX-8371;
NCIt synonyms : Anti-PD-1/PD-L1 Bispecific Antibody CTX-8371; PD-1 x PD-L1 Bispecific Antibody CTX-8371;
NCIt definition : A bispecific tetravalent antibody targeting both the human negative immunoregulatory
checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and its ligand,
human programmed death-ligand 1 (PD-L1; CD274), with potential checkpoint inhibitory,
immunostimulating and antineoplastic activities. Upon administration, anti-PD-1/anti-PD-L1
bispecific antibody CTX-8371 simultaneously targets and binds to PD-1, which is expressed
on a variety of leukocyte subsets including activated T-lymphocytes in the tumor microenvironment
(TME), and PD-L1, which is expressed on tumor cells. This crosslinks PD-1-expressing
T cells and PD-L1-expressing tumor cells, and prevents PD-L1 from binding to and activating
its receptor PD-1, which inhibits the PD-L1/PD-1-mediated downregulation of T-cell
activation and proliferation. This reverses T-cell inactivation caused by PD-L1/PD-1
signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated
anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1 binding to
PD-1 on activated T-cells inhibits the expansion and survival of CD8-positive T-cells,
suppresses the immune system and results in immune evasion.;
Molecule name : CTX-8371; CTX 8371;
NCI Metathesaurus CUI : CL1926434;
Origin ID : C204167;
UMLS CUI : C5908036;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
